Asia-Pacific: Market for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses 2022

Market Size for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Asia-Pacific

In 2021, the Asia-Pacific human and animal blood market decreased by -X% to $X for the first time since 2015, thus ending a five-year rising trend. The total consumption indicated a resilient increase from 2012 to 2021: its value increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, consumption increased by +X% against 2013 indices. The level of consumption peaked at $X in 2020, and then shrank slightly in the following year.

Production of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Asia-Pacific

In value terms, human and animal blood production dropped to $X in 2021 estimated in export price. The total production indicated a resilient expansion from 2012 to 2021: its value increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, production increased by +X% against 2013 indices. The growth pace was the most rapid in 2014 when the production volume increased by X% against the previous year. The level of production peaked at $X in 2020, and then dropped slightly in the following year.

Exports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Exports in Asia-Pacific

In 2021, shipments abroad of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses increased by X% to X tons, rising for the sixth year in a row after two years of decline. Total exports indicated prominent growth from 2012 to 2021: its volume increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, exports increased by +X% against 2015 indices. As a result, the exports reached the peak and are likely to continue growth in the immediate term.

In value terms, human and animal blood exports expanded slightly to $X in 2021. Over the period under review, exports saw prominent growth. The most prominent rate of growth was recorded in 2018 when exports increased by X%. The level of export peaked in 2021 and is expected to retain growth in the near future.

Exports by Country

The shipments of the three major exporters of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses, namely India, Australia and China, represented more than half of total export. South Korea (X tons) held a X% share (based on physical terms) of total exports, which put it in second place, followed by New Zealand (X%) and Hong Kong SAR (X%). The following exporters - Japan (X tons) and Thailand (X tons) - together made up X% of total exports.

From 2012 to 2021, the most notable rate of growth in terms of shipments, amongst the leading exporting countries, was attained by India (with a CAGR of +X%), while the other leaders experienced more modest paces of growth.

In value terms, South Korea ($X) remains the largest human and animal blood supplier in Asia-Pacific, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports. It was followed by Australia, with a X% share.

In South Korea, human and animal blood exports expanded at an average annual rate of +X% over the period from 2012-2021. In the other countries, the average annual rates were as follows: China (+X% per year) and Australia (+X% per year).

Export Prices by Country

The export price in Asia-Pacific stood at $X per ton in 2021, shrinking by -X% against the previous year. Over the period under review, the export price, however, continues to indicate a prominent expansion. The growth pace was the most rapid in 2018 when the export price increased by X% against the previous year. The level of export peaked at $X per ton in 2020, and then contracted dramatically in the following year.

Prices varied noticeably by the country of origin: the country with the highest price was South Korea ($X per ton), while Thailand ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by New Zealand (+X%), while the other leaders experienced more modest paces of growth.

Imports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Imports in Asia-Pacific

Human and animal blood imports skyrocketed to X tons in 2021, rising by X% against the previous year. In general, imports continue to indicate a strong increase. As a result, imports attained the peak and are likely to continue growth in the immediate term.

In value terms, human and animal blood imports soared to $X in 2021. Over the period under review, imports posted a prominent increase. The most prominent rate of growth was recorded in 2017 when imports increased by X% against the previous year. Over the period under review, imports reached the maximum in 2021 and are likely to continue growth in the near future.

Imports by Country

In 2021, China (X tons), distantly followed by Malaysia (X tons), Australia (X tons), India (X tons), Japan (X tons), Vietnam (X tons), Thailand (X tons) and South Korea (X tons) were the largest importers of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses, together making up X% of total imports.

From 2012 to 2021, the biggest increases were in Vietnam (with a CAGR of +X%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, China ($X) constitutes the largest market for imported human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses in Asia-Pacific, comprising X% of total imports. The second position in the ranking was taken by Japan ($X), with a X% share of total imports. It was followed by Australia, with a X% share.

In China, human and animal blood imports increased at an average annual rate of +X% over the period from 2012-2021. In the other countries, the average annual rates were as follows: Japan (+X% per year) and Australia (+X% per year).

Import Prices by Country

In 2021, the import price in Asia-Pacific amounted to $X per ton, picking up by X% against the previous year. Over the period from 2012 to 2021, it increased at an average annual rate of +X%. The pace of growth was the most pronounced in 2017 when the import price increased by X% against the previous year. Over the period under review, import prices attained the peak figure at $X per ton in 2018; however, from 2019 to 2021, import prices failed to regain momentum.

There were significant differences in the average prices amongst the major importing countries. In 2021, the country with the highest price was Japan ($X per ton), while Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by South Korea (+X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :